CD274 and colorectal cancer: Because of increased immune recognition, an MSI-H/dMMR status is a predictive biomarker for benefit with immune checkpoint blockade with anti-programmed death-(ligand) 1 [anti-PD-(L)1] treatments not only for colorectal cancer (10) but also for other solid tumors (11–13).